Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema

Eli Lilly (NYSE: LLY) and Incyte (NASDAQ: INCY) are marching forward in their quest to gain regulatory approval for Olumiant as a treatment for atopic dermatitis (AD), commonly referred to as eczema. and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-Phase-3-Study-BREEZE-AD5-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe.html

Last month, the companies showed that the drug in combination with topical corticosteroids helped patients reduce their eczema symptoms. And now the healthcare companies have demonstrated that the monotherapy is able to help eczema patients as well.

Doctor looking at a patient's arm

Image source: Getty Images.

In the Breeze-AD5 study, 29.5% of patients taking the higher dose of Olumiant had at least a 75% or greater change from baseline in their Eczema Area and Severity Index score (EASI75), compared with 8.2% of patients taking placebo. The lower dose of Olumiant helped 12.9% of patients reach the goal, but the result wasn't statistically better than a placebo.

The higher dose also helped 24% of patients reach clear or almost clear skin, with at least a 2-point improvement on the validated Investigator's Global Assessment for AD, compared with 5.4% of patients taking a placebo. The lower dose helped 12.9% of patients reach the goal, which was statistically better than the placebo result.

A third endpoint that measured itch sensitivity also showed that both doses worked better than a placebo, with the higher dose producing a better result than the lower dose, as expected.

Olumiant is already approved to treat rheumatoid arthritis, but an expansion into eczema would expand the potential market for the drug substantially. Eli Lilly has applied for expanded approval to treat eczema in the EU. With the final clinical trial in the Breeze clinical trial program complete, the company plans to submit marketing applications to expand the approval in the U.S. and Japan this year.

10 stocks we like better than Eli Lilly
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Eli Lilly wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of December 1, 2019


Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Incyte. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More